SLNO - Soleno Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$80.00
DETAILS
HIGH:
$107.00
LOW:
$53.00
MEDIAN:
$80.00
CONSENSUS:
$80.00
UPSIDE:
50.91%
About Soleno Therapeutics, Inc. (https://soleno.life)
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Anish Bhatnagar | Chairman, President & CEO | 1970 | $1,230,740 USD |
| James H. MacKaness | Executive Officer | 1964 | $734,908 USD |
| Meredith Manning | Chief Commercial Officer | 1972 | $676,588 USD |
| Jennifer Fulk | Chief Financial Officer | 1977 | $640,000 USD |
| Patricia C. Hirano | Senior Vice President of Regulatory Affairs | 1966 | $515,813 USD |
| Manher A. Joshi | Chief Development Officer | 1968 | $514,721 USD |
| Kevin Norrett | Chief Business Officer | 1973 | $487,331 USD |
| Kristen Yen | Senior Vice President of Global Clinical Operations and Patient Advocacy | 1969 | $317,190 USD |
| Dairine Dempsey | Senior Vice President of Europe | – | – |
| Jesse Schumaker | General Counsel | – | – |
| Lauren Budesheim | Senior Vice President of People | – | – |
| Michael Huang | Senior Vice President of Clinical Development | 1974 | – |
| Mitchell Nagao | Senior Vice President of Medical Affairs | – | – |
| Neil Cowen | Senior Vice President of New Product Planning | – | – |